Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, Bethesda, Maryland.
Safety and Epidemiology Research, HealthCore Inc., Wilmington, Delaware.
Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):496-502. doi: 10.1158/1055-9965.EPI-17-0853. Epub 2018 Feb 23.
Evidence suggests that natural antibodies developed after HPV16 infection may protect some women but not men against subsequent HPV16 reacquisition. Less is known whether antibodies developed following HPV16 infection are protective among men who have sex with men (MSM). Four hundred seventy-five MSM from the Human Papillomavirus Infection in Men (HIM) study were tested for serum antibodies to HPV16 L1 using enzyme-linked immunosorbent assays, and for anal and genital HPV16 DNA using PCR consensus primer system (PGMY 09/11). Adjusted Cox regression was used to evaluate whether baseline HPV16 seropositivity impacts subsequent genital or anal HPV16 DNA. The risk of subsequent genital HPV16 [aHR = 1.05, 95% confidence interval (CI) = 0.66-1.68] and anal HPV16 infections among MSM (aHR = 2.34, 95% CI = 0.92-5.98) was similar or nonsignificantly higher in HPV16-seropositive than HPV16-seronegative MSM. The risk of genital HPV16 was also similar between HPV16-seronegative and HPV16-seropositive MSM in the highest tertile of HPV16 antibody levels and when restricting to those with new sex partners during follow-up ( > 0.20). Among the 118 MSM who were HPV16 seropositive, 90% remained HPV16 seropositive up to 4 years later. When tested together, MSM with the highest antibody titers (top tertile) had similar levels to females (mean = 130.3 vs. 134.5 EU/mL, = 0.84). Despite years of HPV16 seropositivity persistence and antibody titers comparable with females, this study suggested no evidence of HPV16 natural antibodies protecting against subsequent genital or anal HPV16 infection in MSM. This could help partially explain the high incidence of genital and anal HPV16 infection and related anal cancer seen in middle-aged and older MSM. .
有证据表明，HPV16 感染后产生的天然抗体可能会保护部分女性，但不会保护男性免受随后的 HPV16 再感染。对于男男性行为者（MSM）中，HPV16 感染后产生的抗体是否具有保护作用，目前了解较少。本研究利用酶联免疫吸附试验（ELISA）检测 475 名来自男性 HPV 感染研究（HIM）的男性血清 HPV16 L1 抗体，利用聚合酶链反应共识引物系统（PGMY 09/11）检测肛门和生殖器 HPV16 DNA。采用调整后的 Cox 回归模型来评估基线 HPV16 血清阳性是否会影响随后的生殖器或肛门 HPV16 DNA。MSM 中，与 HPV16 血清阴性者相比，HPV16 血清阳性者的生殖器 HPV16 感染的风险[aHR = 1.05，95%置信区间（CI）= 0.66-1.68]和肛门 HPV16 感染的风险[aHR = 2.34，95%CI = 0.92-5.98]相似或无显著差异。HPV16 抗体水平最高三分位数的 HPV16 血清阴性者和随访期间有新性伴侣的 HPV16 血清阴性者中，生殖器 HPV16 感染的风险也与 HPV16 血清阳性者相似（>0.20）。在 118 名 HPV16 血清阳性的 MSM 中，90%在 4 年后仍保持 HPV16 血清阳性。当联合检测时，抗体滴度最高的 MSM（最高三分位数）与女性的抗体滴度相似（均值=130.3 与 134.5 EU/mL， = 0.84）。尽管 HPV16 血清阳性持续多年，抗体滴度与女性相当，但本研究并未发现 MSM 的 HPV16 天然抗体可预防随后的生殖器或肛门 HPV16 感染。这可以部分解释中年和老年 MSM 中生殖器和肛门 HPV16 感染及相关肛门癌发病率高的原因。
